Clinical Predictors of Relapse in a Cohort of Steroid-Treated Patients With Well-Controlled Myasthenia Gravis

OBJECTIVE: Despite the high efficiency of glucocorticoids (GCs), ~18–34% patients with myasthenia gravis (MG) may experience relapses of the disease. Here, we aim to identify clinical factors related to relapses during steroid tapering or after withdrawal in MG patients who were well-managed on ster...

Descripción completa

Detalles Bibliográficos
Autores principales: Su, Shengyao, Lei, Lin, Fan, Zhirong, Zhang, Shu, Wen, Qi, Wang, Jingsi, Lu, Yan, Di, Li, Wang, Min, Chen, Hai, Da, Yuwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8854248/
https://www.ncbi.nlm.nih.gov/pubmed/35185767
http://dx.doi.org/10.3389/fneur.2022.816243

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8854248/
https://www.ncbi.nlm.nih.gov/pubmed/35185767
http://dx.doi.org/10.3389/fneur.2022.816243

Ejemplares similares